Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization

被引:65
作者
Leung, Wai-Hang [1 ]
Gay, Joel [1 ]
Martin, Unja [1 ]
Garrett, Tracy E. [1 ]
Horton, Holly M. [1 ]
Certo, Michael T. [1 ]
Blazar, Bruce R. [2 ]
Morgan, Richard A. [1 ]
Gregory, Philip D. [1 ]
Jarjour, Jordan [1 ]
Astrakhan, Alexander [1 ]
机构
[1] Bluebird Bio Inc, Cambridge, MA 02142 USA
[2] Univ Minnesota, Dept Pediat, Div Blood & Marrow Transplantat, Minneapolis, MN 55455 USA
关键词
ACUTE LYMPHOBLASTIC-LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; BINDING DOMAIN; RAPAMYCIN; THERAPY; CANCER; SPECIFICITY; ACTIVATION; EXHAUSTION; STRATEGY;
D O I
10.1172/jci.insight.124430
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Chimeric antigen receptor (CAR) T cell therapies have achieved promising outcomes in several cancers, however more challenging oncology indications may necessitate advanced antigen receptor designs and functions. Here we describe a bipartite receptor system comprised of separate antigen targeting and signal transduction polypeptides, each containing an extracellular dimerization domain. We demonstrate that T cell activation remains antigen dependent but can only be achieved in the presence of a dimerizing drug, rapamycin. Studies performed in vitro and in xenograft mouse models illustrate equivalent to superior anti-tumor potency compared to currently used CAR designs, and at rapamycin concentrations well below immunosuppressive levels. We further show that the extracellular positioning of the dimerization domains enables the administration of recombinant re-targeting modules, potentially extending antigen targeting. Overall, this novel regulatable CAR design has exquisite drug sensitivity, provides robust anti-tumor responses, and is uniquely flexible for multiplex antigen targeting or retargeting, which may further assist the development of safe, potent and durable T cell therapeutics.
引用
收藏
页数:18
相关论文
共 50 条
[41]   Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth [J].
Sun, Fumou ;
Cheng, Yan ;
Wanchai, Visanu ;
Guo, Wancheng ;
Mery, David ;
Xu, Hongwei ;
Gai, Dongzheng ;
Siegel, Eric ;
Bailey, Clyde ;
Ashby, Cody ;
Al Hadidi, Samer ;
Schinke, Carolina ;
Thanendrarajan, Sharmilan ;
Ma, Yupo ;
Yi, Qing ;
Orlowski, Robert Z. ;
Zangari, Maurizio ;
van Rhee, Frits ;
Janz, Siegfried ;
Bishop, Gail ;
Tricot, Guido ;
Shaughnessy, John D. ;
Zhan, Fenghuang .
NATURE COMMUNICATIONS, 2024, 15 (01)
[42]   A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors [J].
Liu, Xiaojun ;
Ranganathan, Raghuveer ;
Jiang, Shuguang ;
Fang, Chongyun ;
Sun, Jing ;
Kim, Soyeon ;
Newick, Kheng ;
Lo, Albert ;
June, Carl H. ;
Zhao, Yangbing ;
Moon, Edmund K. .
CANCER RESEARCH, 2016, 76 (06) :1578-1590
[43]   Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells [J].
Kath, Jonas ;
Du, Weijie ;
Pruene, Alina ;
Braun, Tobias ;
Thommandru, Bernice ;
Turk, Rolf ;
Sturgeon, Morgan L. ;
Kurgan, Gavin L. ;
Amini, Leila ;
Stein, Maik ;
Zittel, Tatiana ;
Martini, Stefania ;
Ostendorf, Lennard ;
Wilhelm, Andreas ;
Akyuez, Levent ;
Rehm, Armin ;
Hoepken, Uta E. ;
Pruss, Axel ;
Kunkele, Annette ;
Jacobi, Ashley M. ;
Volk, Hans-Dieter ;
Schmueck-Henneresse, Michael ;
Stripecke, Renata ;
Reinke, Petra ;
Wagner, Dimitrios L. .
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2022, 25 :311-330
[44]   Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line [J].
Kang, Chung Hyo ;
Kim, Yeongrin ;
Lee, Heung Kyoung ;
Lee, So Myoung ;
Jeong, Hye Gwang ;
Choi, Sang Un ;
Park, Chi Hoon .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (23) :1-12
[45]   T Cells Expressing CAR Equipped With Extracellular Domain of BTLA Are Effective Against HVEM-over-expressing Melanoma Cell Lines [J].
Kim, Yeongrin ;
Kim, Ji Eun ;
Lee, Da Yeon ;
Choi, Ji U. ;
Park, Jin Song ;
Lee, Heung Kyoung ;
Choi, Sang Un ;
Park, Simon ;
Park, Chi Hoon .
ANTICANCER RESEARCH, 2023, 43 (08) :3419-3427
[46]   Stem cell-derived CAR T cells show greater persistence, trafficking, and viral control compared to ex vivo transduced CAR T cells [J].
Carrillo, Mayra A. ;
Zhen, Anjie ;
Mu, Wenli ;
Rezek, Valerie ;
Martin, Heather ;
Peterson, Christopher W. ;
Kiem, Hans-Peter ;
Kitchen, Scott G. .
MOLECULAR THERAPY, 2024, 32 (04) :1000-1015
[47]   Tumor-derived extracellular vesicles induce invalid cytokine release and exhaustion of CD19 CAR-T Cells [J].
Zhu, Xiaoying ;
Hu, Hui ;
Xiao, Yi ;
Li, Qing ;
Zhong, Zhaodong ;
Yang, Jingmin ;
Zou, Ping ;
Cao, Yang ;
Meng, Fankai ;
Li, Wei ;
You, Yong ;
Guo, An-Yuan ;
Zhu, Xiaojian .
CANCER LETTERS, 2022, 536
[48]   Chimeric Antigen Receptor (CAR) Regulatory T-Cells in Solid Organ Transplantation [J].
Gille, Ilse ;
Claas, Frans H. J. ;
Haasnoot, Geert W. ;
Heemskerk, Mirjam H. M. ;
Heidt, Sebastiaan .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[49]   Memory T Cells in the Chronic Inflammatory Microenvironment of Nasal Polyposis are Hyporesponsive to Signaling Through the T Cell Receptor [J].
Lehman, Heather K. ;
Simpson-Abelson, Michelle R. ;
Conway, Thomas F., Jr. ;
Kelleher, Raymond J., Jr. ;
Bernstein, Joel M. ;
Bankert, Richard B. .
JARO-JOURNAL OF THE ASSOCIATION FOR RESEARCH IN OTOLARYNGOLOGY, 2012, 13 (03) :423-435
[50]   Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells [J].
Strohl, William R. ;
Naso, Michael .
ANTIBODIES, 2019, 8 (03)